An anti-Müllerian hormone (AMH) test in males mainly reflects Sertoli-cell activity in the testes. AMH is best known for its role in fetal male development, when it causes regression of the Müllerian ducts. After birth, concentrations remain high through childhood and fall sharply during puberty as Sertoli cells mature under rising intratesticular testosterone. In adult men, AMH testing is less routine than testosterone, FSH, LH, semen analysis, or inhibin B. It can still add value in selected cases involving absent or abnormal testes, undescended testes, delayed puberty, disorders of sex development, severe male infertility, nonobstructive azoospermia, or questions about residual Sertoli-cell function. A result cannot be interpreted with one universal adult cutoff because age, pubertal stage, assay, testicular volume, FSH stimulation, and androgen exposure all influence the value. Low AMH may support impaired Sertoli-cell function, but it does not prove infertility or predict sperm retrieval with certainty.
- AMH in males is produced by Sertoli cells, the testicular cells that support sperm development.
- AMH is naturally high before puberty and much lower in adult men, so age- and puberty-specific ranges are essential.
- Low adult AMH may accompany poor semen quality, smaller testes, high FSH, or nonobstructive azoospermia, but it is not diagnostic by itself.
- Normal or high AMH does not guarantee normal sperm production, because immature or dysregulated Sertoli cells may still secrete AMH.
- Semen analysis, FSH, inhibin B, testosterone, examination, and ultrasound often matter more than AMH alone.
Table of Contents
- What AMH does in males
- When AMH testing is useful
- Testing methods and reference ranges
- What low AMH can mean
- What normal or high AMH can mean
- AMH in male infertility and azoospermia
- How AMH fits with other hormone and fertility tests
- Follow-up, limitations, and next steps
What AMH does in males
AMH is a glycoprotein hormone in the transforming growth factor beta family. In the male fetus, Sertoli cells begin producing AMH early in development. The hormone causes the paired Müllerian ducts to regress, preventing development of structures that would otherwise form the uterus, fallopian tubes, and upper vagina. Testosterone from fetal Leydig cells supports development of the Wolffian ducts and male internal reproductive tract, while dihydrotestosterone supports formation of external male genital structures.
This division explains why AMH can answer a different question from testosterone. A newborn or child may have functioning Sertoli tissue and measurable AMH even when Leydig-cell testosterone production is impaired. Conversely, a defect in AMH production or signaling can allow Müllerian structures to persist despite otherwise typical male virilization.
After birth, AMH remains relatively high because immature Sertoli cells produce it actively. FSH can stimulate AMH production during childhood. At puberty, intratesticular testosterone rises and Sertoli cells mature. Mature Sertoli cells reduce AMH secretion into the bloodstream, so circulating levels fall to a small fraction of childhood concentrations. This is a normal developmental change rather than loss of the testes.
Adult AMH therefore represents a balance among Sertoli-cell number, maturation, FSH stimulation, intratesticular androgen action, and testicular pathology. It is not a direct measure of serum testosterone, sperm count, or fertility potential. A man can have normal testosterone and low AMH if Sertoli-cell function is impaired. He can also have low testosterone and an AMH pattern that reflects immature Sertoli cells rather than absent testicular tissue.
AMH is released into both the circulation and the seminiferous-tubule compartment. After puberty, a larger proportion may be directed toward the tubular lumen, which helps explain why serum AMH becomes low even though Sertoli cells remain present. Seminal-plasma AMH has been studied as a fertility marker, but it is not a standard clinical test in most laboratories.
The hormone’s developmental biology makes it particularly useful in infants and children. In adult men, its role is more selective and often investigational. It should not be marketed as a simple “testicular reserve” number equivalent to ovarian AMH in women.
When AMH testing is useful
AMH may be ordered when a clinician needs evidence that functioning Sertoli-cell tissue is present or wants another marker of seminiferous-tubule function.
Potential uses include:
- Evaluating nonpalpable or undescended testes in infants and children
- Distinguishing absent testes from testes that are present but not located normally
- Assessing some disorders of sex development
- Investigating persistent Müllerian duct syndrome
- Evaluating delayed puberty or suspected congenital hypogonadotropic hypogonadism
- Assessing Sertoli-cell function in boys receiving gonadotoxic treatment
- Investigating severe oligospermia or azoospermia in selected adult men
- Contributing to prediction models before testicular sperm extraction
- Monitoring rare Sertoli-cell tumors or other specialized conditions
In a child with nonpalpable testes, detectable AMH supports the presence of testicular tissue because Sertoli cells are the main source. Very low or undetectable AMH may support anorchia, but the result must be interpreted with age, assay sensitivity, hCG stimulation results, testosterone, inhibin B, imaging, and examination. A single test cannot always distinguish absent testes from severely damaged or dysgenetic testes.
In delayed puberty, AMH can help assess whether Sertoli cells remain in an immature prepubertal state. Boys with central hypogonadism may have relatively high AMH for age because intratesticular testosterone has not risen enough to drive Sertoli maturation. FSH stimulation may be inadequate, however, so the exact pattern varies. The LH result, FSH, testosterone, inhibin B, testicular size, and pubertal history remain central.
In adult infertility, AMH is not usually part of the minimum initial workup. Semen analysis identifies the sperm abnormality directly, while FSH, testosterone, and examination often classify the endocrine pattern. AMH may be added in severe cases, research-oriented centers, or when clinicians are estimating the chance of finding sperm during microdissection testicular sperm extraction.
AMH is not a screening test for erectile dysfunction, low libido, fatigue, or routine testosterone deficiency. Those symptoms call for a standard androgen evaluation rather than an isolated Sertoli-cell marker.
Testing methods and reference ranges
AMH is measured in serum or plasma with an immunoassay. Laboratories may report ng/mL, pmol/L, or another unit. A commonly used approximate conversion is:
- 1 ng/mL is about 7.14 pmol/L
- 1 pmol/L is about 0.14 ng/mL
The laboratory’s own conversion and report should be followed because assay calibration can differ.
No single adult male range applies to every method. Concentrations vary dramatically across life. They are high in infancy and childhood, decline during puberty, and remain much lower in adulthood. A result must be compared with an age- and sex-specific interval, and pediatric interpretation may also require Tanner stage.
Assay differences are a major limitation. Older and newer AMH platforms use different antibodies and calibration systems. A value measured by one assay may not be directly comparable with a value from another. Serial monitoring is most reliable when the same laboratory and method are used.
Pre-analytical details still matter when results are being compared over time. The sample type, storage conditions, recent treatment, and laboratory platform should be documented. Biotin-containing supplements can interfere with some immunoassays, depending on the assay design, so patients should report high-dose biotin used for hair, nail, or neurologic indications. The laboratory can advise whether temporary interruption is needed; prescribed therapy should never be stopped without approval.
Results should also be interpreted against developmental history. Premature birth, cryptorchidism, prior orchiopexy, childhood chemotherapy, testicular torsion, mumps orchitis, and pubertal timing can all affect adult Sertoli-cell markers. A current AMH value cannot reconstruct the exact timing or severity of earlier injury, but the history may explain why AMH, inhibin B, FSH, testicular volume, and semen results do not align perfectly.
AMH usually does not require fasting, and it has less pronounced daily variation than testosterone. Still, the laboratory’s preparation instructions should be followed. Tell the clinician about testosterone therapy, gonadotropins, selective estrogen receptor modulators, aromatase inhibitors, chemotherapy, radiation, recent testicular surgery, and medications that alter the reproductive axis.
Testosterone exposure can affect AMH indirectly by changing Sertoli-cell maturation and intratesticular androgen action. Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and sperm production even while serum testosterone rises. The resulting AMH response is not simple, so treatment history must be included in interpretation.
A report may flag an adult AMH value as low without establishing disease. Some healthy fertile men have low serum concentrations, and overlap between fertile and infertile groups is substantial. The meaningful questions are whether the result matches testicular size, FSH, inhibin B, semen findings, diagnosis, and the clinical decision being considered.
What low AMH can mean
Low AMH in a male generally suggests reduced Sertoli-cell mass, altered Sertoli-cell function, advanced Sertoli maturation, or a combination of these factors. The significance depends strongly on age.
In a prepubertal boy, unexpectedly low or undetectable AMH can raise concern for absent testes, severe testicular dysgenesis, damaged Sertoli cells, or a defect in AMH production. Because normal boys usually have clearly measurable concentrations, a low childhood result may be more informative than the same result in an adult.
In an adolescent, falling AMH may be a normal sign that intratesticular testosterone is rising and Sertoli cells are maturing. Interpretation must be tied to pubertal stage. Low AMH with normal progression of testicular enlargement, testosterone rise, and secondary sexual development may be expected. Low AMH without other pubertal changes may require a different explanation.
In an adult man, low AMH may occur with:
- Reduced Sertoli-cell number or function
- Small testicular volume
- Severe impairment of spermatogenesis
- Nonobstructive azoospermia
- Prior chemotherapy or pelvic/testicular radiation
- Testicular torsion, infection, trauma, or surgery
- Klinefelter syndrome or other chromosomal conditions
- Long-standing testicular failure
- Normal adult physiology, depending on the assay and range
Studies have found associations between lower AMH and poorer semen quality, lower inhibin B, higher FSH, smaller testes, and worse gonadal-function markers in some infertile populations. Association is not the same as diagnosis. Considerable overlap remains, and some men with low AMH still produce sperm.
Low AMH also does not reveal whether sperm are absent because of obstruction or production failure. In obstructive azoospermia, testicular sperm production can be normal even though no sperm enter the ejaculate. Serum AMH may not reliably separate obstruction from nonobstructive disease. History, examination, semen volume and pH, FSH, testicular size, imaging, and genetic evaluation are more informative.
A low result should not lead to AMH replacement. AMH is not an approved fertility treatment, and raising the serum number has not been shown to restore spermatogenesis. Treatment focuses on the underlying cause when one is reversible.
What normal or high AMH can mean
A normal adult AMH result shows that measurable Sertoli-cell secretion is present, but it does not prove normal fertility. Sperm development depends on germ cells, Sertoli support, FSH, high intratesticular testosterone, intact ducts, normal ejaculation, and many genetic and environmental factors.
A relatively high AMH result may reflect:
- Normal biological variation
- A younger age within the adult range
- Increased Sertoli-cell number
- FSH stimulation
- Incomplete Sertoli-cell maturation
- Reduced intratesticular androgen action
- Androgen insensitivity or impaired androgen signaling
- Central hypogonadism before adequate pubertal induction
- Rare Sertoli-cell tumors or other uncommon conditions
In delayed puberty or hypogonadotropic hypogonadism, AMH can remain higher than expected because Sertoli cells have not fully matured under intratesticular testosterone. At the same time, low FSH may reduce Sertoli stimulation, so some patients do not show a high value. This is why AMH must be interpreted with both gonadotropins and testosterone.
Androgen insensitivity can produce persistent AMH because Sertoli cells do not receive normal androgen signaling despite the presence of testosterone. The phenotype and hormone pattern vary with the degree of receptor dysfunction. AMH is one part of a specialized endocrine and genetic evaluation.
Rare Sertoli-cell tumors can produce AMH, but an isolated mild elevation is not a tumor marker by itself. A testicular mass, asymmetry, pain, gynecomastia, rapid hormonal change, or other abnormal imaging findings would carry more weight. Ultrasound and specialist evaluation are required when a mass is suspected.
A high result should not be interpreted as “high sperm reserve.” Unlike ovarian AMH, where the marker has an established relationship with the pool of recruitable follicles, male AMH does not provide a direct count of sperm-producing capacity. The analogy is appealing but clinically misleading.
AMH in male infertility and azoospermia
Male infertility evaluation begins with reproductive history, examination, and at least one properly collected semen analysis. Hormone testing is added when sperm concentration is low, sexual symptoms are present, testes are small, or an endocrine disorder is suspected. AMH is an adjunct, not a replacement for this framework.
The strongest current interest is in nonobstructive azoospermia, where sperm production is severely impaired or patchy. Microdissection testicular sperm extraction searches testicular tissue for small areas of active spermatogenesis. Researchers have studied AMH, FSH, inhibin B, testicular volume, genetics, and other markers as predictors of successful sperm retrieval.
No blood marker predicts the outcome perfectly. High FSH does not prove that no sperm are present, and low AMH does not guarantee failure. Testicular histology can be heterogeneous; a small focus of sperm production may exist despite unfavorable serum markers. Prediction models may estimate probability, but they should not be used as the sole reason to deny a potentially appropriate procedure.
A recent systematic review and meta-analysis examined FSH, inhibin B, and AMH for predicting sperm retrieval in men with nonobstructive azoospermia. These markers showed associations but limited stand-alone accuracy. Clinical decisions still depend on diagnosis, genetics, prior surgery, testicular volume, clinician experience, and the couple’s reproductive goals.
AMH may be more informative when combined with FSH. Low AMH plus high FSH supports impaired Sertoli-cell and seminiferous-tubule function more strongly than either result alone. Even then, semen analysis and the underlying diagnosis remain essential.
For men with oligospermia rather than azoospermia, lower AMH has been associated with lower sperm concentration and count in some cohorts. Other studies have found weak or inconsistent relationships. Differences in assay, population, age, disease cause, and sample size likely explain part of the disagreement.
The inhibin B test in men is often considered alongside AMH because both come from Sertoli cells. Inhibin B has a closer feedback relationship with FSH and active spermatogenesis, while AMH reflects Sertoli differentiation and function in a different way. Neither marker replaces semen testing.
How AMH fits with other hormone and fertility tests
AMH becomes easier to interpret when paired with tests that assess different parts of the reproductive system.
How AMH complements other male reproductive tests
| Test | Main information | How it relates to AMH |
|---|---|---|
| FSH | Pituitary stimulation of Sertoli cells | High FSH with low AMH supports seminiferous-tubule impairment |
| Inhibin B | Sertoli-cell feedback and spermatogenic activity | Low values together strengthen concern for impaired Sertoli function |
| LH and testosterone | Leydig-cell and pituitary function | Help determine whether low intratesticular androgen signaling may alter AMH |
| Semen analysis | Sperm concentration, motility, morphology, volume, and other features | Directly evaluates the fertility outcome AMH only approximates |
| Testicular ultrasound | Structure, location, masses, and some volume information | Provides anatomy when AMH suggests tissue is present or impaired |
| Genetic tests | Karyotype, Y-chromosome deletions, or condition-specific variants | Identify causes that AMH cannot distinguish |
A typical pattern in primary seminiferous-tubule failure is high FSH, low inhibin B, small testes, poor semen parameters, and sometimes low AMH. Testosterone may remain normal if Leydig cells are preserved. In central hypogonadism, LH and FSH are low or inappropriately normal, testosterone is low, and AMH may remain relatively high because Sertoli maturation is incomplete.
In a boy with nonpalpable testes, AMH and inhibin B may both be low when testicular tissue is absent. Detectable values support the presence of Sertoli cells, but imaging and surgical exploration may still be required. hCG stimulation assesses Leydig-cell testosterone production and answers a different question.
A male fertility hormone panel provides a broader view of pituitary, Leydig-cell, and Sertoli-cell function. AMH is added selectively when its distinct biology will change interpretation or counseling.
Follow-up, limitations, and next steps
An abnormal result should first be checked against the correct age, sex, pubertal stage, unit, and assay. If the finding is unexpected, repeating the measurement at the same laboratory may be reasonable before making a major decision.
Possible follow-up includes:
- FSH, LH, total testosterone, SHBG, and free testosterone
- Inhibin B
- One or more semen analyses
- Testicular examination and ultrasound
- hCG stimulation testing in selected pediatric cases
- Karyotype or Y-chromosome microdeletion testing in severe infertility
- Condition-specific genetic testing for disorders of sex development
- Pituitary evaluation when gonadotropins and testosterone suggest central disease
- Reproductive-urology consultation before sperm-retrieval procedures
AMH has several limitations. Assays are not fully interchangeable, adult reference intervals are broad, concentrations overlap between fertile and infertile men, and the result does not identify the exact histologic pattern in the testes. Treatment, puberty, androgen action, FSH, age, and testicular volume all affect interpretation.
Common mistakes include treating AMH as a direct sperm-count test, comparing a male result with a female ovarian-reserve range, assuming low AMH proves irreversible infertility, or assuming normal AMH guarantees successful sperm retrieval. Another error is ordering AMH before completing more informative basic tests.
Seek prompt care for sudden testicular pain, a hard testicular lump, rapidly increasing scrotal swelling, severe headache with visual change, or acute symptoms after gonadotoxic treatment. AMH itself does not create an emergency, but the condition being investigated may require timely evaluation.
Used carefully, AMH can confirm the presence of Sertoli-cell activity, add context to pubertal disorders, and refine selected infertility assessments. Its value lies in answering a focused question alongside semen analysis, gonadotropins, inhibin B, testosterone, anatomy, and genetics—not in replacing them or turning a complex fertility assessment into one score.
An adult AMH value should not be converted into a personal fertility percentage. Two men with the same concentration may have different testicular volume, FSH, semen findings, genetic diagnoses, and chances of focal sperm production. The result is most useful when it changes a defined next step, such as pediatric assessment of testicular tissue or specialist counseling in azoospermia.
References
- Anti-Müllerian hormone, testicular descent and cryptorchidism 2024 (Review)
- Role of Follicle-stimulating Hormone, Inhibin B, and Anti-Müllerian Hormone in Predicting Sperm Retrieval in Men with Nonobstructive Azoospermia Undergoing Microdissection Testicular Sperm Extraction: A Systematic Review and Meta-analysis 2024 (Systematic Review)
- Low serum anti-Müllerian hormone is associated with semen quality in infertile men and not influenced by vitamin D supplementation 2023 (RCT)
- The role of anti-Müllerian hormone for delayed puberty and hypogonadism 2025 (Review)
- Anti-Müllerian Hormone as a Biomarker for Predicting Testicular Sperm Retrieval in Men with Non-Obstructive Azoospermia: A Systematic Review and Meta-Analysis 2025 (Systematic Review)
Disclaimer
This article is educational and does not diagnose infertility, absent testes, a disorder of sex development, or a testicular condition. AMH results require age- and assay-specific interpretation with examination, semen testing, other hormones, imaging, genetics, and the clinical reason for testing. Decisions about fertility treatment or surgery should be made with an appropriate specialist.
